Effect of Anti-IgE Therapy in Patients with Peanut Allergy
Top Cited Papers
- 13 March 2003
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (11), 986-993
- https://doi.org/10.1056/nejmoa022613
Abstract
Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people and cause 50 to 100 deaths per year in the United States. TNX-901 is a humanized IgG1 monoclonal antibody against IgE that recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fcε receptor on mast cells and basophils.This publication has 30 references indexed in Scilit:
- Humanized Anti-IgE mAb Hu-901 Prevents the Activation of Allergen-Specific T CellsInternational Archives of Allergy and Immunology, 2001
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000
- THE HIGH-AFFINITY IgE RECEPTOR (FcεRI): From Physiology to PathologyAnnual Review of Immunology, 1999
- Peanut allergy — current status and future challengesClinical and Experimental Allergy, 1997
- The use of epinephrine in the treatment of anaphylaxisJournal of Allergy and Clinical Immunology, 1994
- Safety of a new, ultrafiltrated whey hydrolysate formula in children with cow milk allergy: a clinical investigationPediatric Allergy and Immunology, 1993
- Safety of casein hydrolysate formula in children with cow milk allergyThe Journal of Pediatrics, 1991
- Double-blind placebo-controlled trial of oral cromolyn in children with atopic dermatitis and documented food hypersensitivityJournal of Allergy and Clinical Immunology, 1988
- Evaluation of immediate adverse reactions to foods in adult patientsJournal of Allergy and Clinical Immunology, 1985
- Increased Plasma Histamine Concentrations after Food Challenges in Children with Atopic DermatitisNew England Journal of Medicine, 1984